C4 Therapeutics 株価情報 (NASDAQ: CCCC)

最新ニュース C4 Therapeutics (NASDAQ:CCCC) 株価情報

C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

C4 Therapeutics Inc

17:30 EDT C4 Therapeutics (CCCC) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...

C4 Therapeutics files $400M mixed securities shelf

17:29 EDT C4 Therapeutics (CCCC) files to sell 4.87M shares of common stock for holders Published first on TheFly – the ultimate source for real-ti...

C4 Therapeutics files to sell 4.87M shares of common stock for holders

C4 Therapeutics, Inc. ( ($CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its inves...

C4 Therapeutics Advances in Protein Degradation Therapy

C4 Therapeutics (CCCC) announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally ...

C4 Therapeutics announces first patient dosed in CFT8919 clinical trial

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Stephens initiated coverage of C4 Therapeutics (CCCC) with an Equal Weight rating and $4 price target The firm is adding to its Biotechnology resea...

C4 Therapeutics initiated with an Equal Weight at Stephens

C4 Therapeutics (CCCC) announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director. Published f...

C4 Therapeutics appoints Hoerter to board of directors

The latest update is out from C4 Therapeutics ( ($CCCC) ). C4 Therapeutics has appointed Steve Hoerter to its Board of Directors, highlighting the ...

C4 Therapeutics Appoints Steve Hoerter to Board

C4 Therapeutics (CCCC) presented clinical data from the ongoing Phase 1 trial of cemsidomide, an orally bioavailable small molecule degrader of IKZ...

C4 Therapeutics presents cemsidomide Phase 1 data at ASH

Wells Fargo analyst Derek Archila upgraded C4 Therapeutics (CCCC) to Overweight from Equal Weight with a price target of $12, up from $8. The share...

C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

CCCC

News

Press Releases

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Management

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Health Care

General

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Earnings

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

ABBV

IMGN

PRTC

Abeona Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Anika Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

aTyr Pharma

Benitec Biopharma

Candel Therapeutics

Cidara Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Chimerix

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharma

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Heron Therapeutics

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

ITeos Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Ocugen

Renovaro

Rezolute

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Vanda Pharmaceuticals Inc. - Common Stock

Comments

C4 Therapeutics

ニュース

最新ニュース C4 Therapeutics (NASDAQ:CCCC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル